The therapeutic era of peptides began in 1921 with the discovery of insulin, a breakthrough that revolutionized diabetes and helped establish biologic therapies in medicine Since then, peptide hormones like oxytocin and human growth hormone (GH) have entered clinical use, and glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide are now widely prescribed for obesity and metabolic diseaseconditions increasingly recognized for their effect on orthopaedic outcomes
Depending on medical evaluation and wellness goals, peptide therapy discussions may include several different programs
The standard weekly dose ranges from 0.25 mg (starting) to 2.4 mg (maximum maintenance)
Therefore, the same NO-therapy effect might indicate a particular match between the similar negative-like symptoms and the similar positive-like symptoms and shared NO-pathology [205,206,207,208,209,210,211,212,213,214,215]